LIFECARE AS
Lifecare ASA is a Bergen-based, Euronext Oslo Børs–listed MedTech company developing Sencell, an implantable osmotic-pressure continuous glucose sensor lasting six months or longer, while also commercialising the RemovAid subdermal implant removal device for health clinics.
- Company typePublic
- Founded1998
- HeadquartersBergen, Norway
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What LIFECARE AS does
Lifecare ASA is a Norwegian clinical-stage MedTech company headquartered in Bergen, developing Sencell, a miniaturised fully-implantable continuous glucose monitor (CGM) the size of a grain of rice (2 × 3 × 6 mm³) that lasts a minimum of six months and transmits data wirelessly to smart devices. The sensor is built on a proprietary osmotic pressure-based detection method — glucose binding molecules inside a closed semipermeable chamber generate measurable pressure variations linearly correlated to glucose concentration — combined with 3D nanoprinting using focused electron-beam technology licensed via NanoBioSensors GmbH in Reutlingen, Germany. The Group operates four core R&D and operating subsidiaries: Lifecare NanoBioSensors GmbH (Reutlingen, sensor/systems development), Lifecare Laboratory GmbH (Mainz, chemistry validation and system evaluation, ISO 9001 and ISO 13485 certified), Lifecare Chemistry Ltd (Bristol, UK, spin-off from University of Bath) and Lifecare Veterinary AS (Bergen, animal-health channel), plus 89.6%-owned RemovAid AS, which sells a CE-marked Class IIa device for subdermal implant removal and is being adapted as the retrieval tool for Sencell.
The business model is currently pre-commercial for the core human CGM line, with revenue mechanics expected to be hardware sales of sensors, transmitters and companion medical mobile applications following CE marking, targeted for human commercialisation in 2027. Lifecare is pursuing a sequenced go-to-market: the veterinary market in Norway is being entered first because it has no specific animal-device regulatory requirements, allowing the company to build manufacturing and product experience; RemovAid provides a small recurring revenue stream from contraceptive implant removal devices in Norwegian health clinics, with planned expansion to Sub-Saharan Africa; an alternative OneTwo Analytics partnership layers data accessibility on top of the Sencell ecosystem. Distribution for Sencell in both human and animal use cases is planned through veterinary clinics and healthcare providers, and a first-in-human clinical trial application is in regulatory review with the Norwegian Medical Products Agency (NOMA) with LINK Medical as regulatory advisor. Following the German subsidiary wind-down announced in 2026, manufacturing and development are being centralised in Bergen and Bristol.
LIFECARE AS firmographics
Firmographics- Name
- LIFECARE AS
- Legal name
- Lifecare ASA
- Website
- https://lifecare.no
- Company type
- Public
- Founded year
- 1998
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Lifecare ASA is a Bergen-based, Euronext Oslo Børs–listed MedTech company developing Sencell, an implantable osmotic-pressure continuous glucose sensor lasting six months or longer, while also commercialising the RemovAid subdermal implant removal device for health clinics.
- Ownership category
- akta.pro rank
LIFECARE AS industry classification
Industry- Product category
- Continuous Glucose Monitoring Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Continuous Glucose Monitoring (CGM) Systems (HLAHAHAA)
- akta.pro secondary industries
- Analytical Development & QC Testing (Release/Stability/Potency) (HLAGAGAF), Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers) (CRACAQAE)
Keywords
Where LIFECARE AS is headquartered
LocationHeadquarters
- HQ city
- Bergen
- HQ country
- Norway
- HQ region
- Europe
Offices6 records
Markets served
LIFECARE AS business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Implantable CGM Sensor Sales (Human): Lifecare will generate revenue from the sale of Sencell implantable CGM sensors for human use. The sensor is implanted under the skin and lasts a minimum of 6 months, with the system including sensor core, transmitter electronics, and mobile medical application. Once CE marking is achieved and clinical trials are completed, the product will be commercialized globally.
- Veterinary Glucose Monitoring System Sales: Lifecare Veterinary sells Sencell-based glucose monitoring systems for diabetic dogs and cats. The veterinary market has lower regulatory barriers, enabling faster commercialization. The product is distributed through veterinary clinics and includes the sensor, transmitter, and mobile app. Norway market entry targeted.
- RemovAid Device Sales: RemovAid develops, manufactures, and distributes medical devices for removal of subdermal implants (including contraceptive implants). The ISO 13485-certified company sells CE-approved Class IIa medical devices to health clinics in Norway as the pilot country, with plans to expand to Sub-Saharan Africa.
- Laboratory Services: Lifecare Laboratory GmbH in Mainz provides commercial services related to clinical research and tests for pharmaceutical and biotechnical industries during the process of approval of drugs and medical devices, as well as general laboratory services for medical institutions.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
LIFECARE AS product offering
Product offeringCore offering
Lifecare AS develops miniaturized implantable nanobiosensors for continuous glucose monitoring, with Sencell as its core product: a wireless implantable CGM sensor approximately the size of a grain of rice (2×3×6 mm³) that uses proprietary osmotic pressure technology, requires no calibration, and lasts a minimum of six months. The portfolio also includes RemovAid (CE-approved Class IIa device for subdermal implant removal), Lifecare Veterinary (Sencell-based glucose monitoring for diabetic dogs and cats), and laboratory services for clinical research. Products are sold through healthcare and veterinary clinics, with commercialization targeted after CE marking.
Product overview
Lifecare AS is a Norwegian MedTech company that has developed Sencell, a miniaturized implantable continuous glucose monitoring sensor using proprietary osmotic pressure technology. The product portfolio includes Sencell as the core human glucose monitoring product, Lifecare Veterinary for pet diabetes applications, and RemovAid (acquired 89.6% in 2024) for subdermal implant removal. The company operates through subsidiaries including Lifecare NanoBioSensors GmbH (sensor development and production in Reutlingen, Germany), Lifecare Laboratory GmbH (chemistry validation and system evaluation in Mainz, Germany), Lifecare Chemistry Ltd (chemical receptors research in Bristol, UK), and Lifecare Veterinary AS (veterinary market execution in Bergen). The Sencell sensor is approximately the size of a grain of rice (2x3x6 mm), lasts minimum 6 months, and transmits glucose data wirelessly to smart devices.
Differentiator
Problem solved
Functional benefit
Brands
- Sencell: Miniature implantable glucose sensor using osmotic pressure technology for continuous glucose monitoring, size of a grain of rice with minimum 6-month lifespan.
- Lifecare Veterinary
- RemovAid
Products and services
- Sencell Sencell is a wireless, fully implantable continuous glucose monitoring sensor approximately the size of a grain of rice (2×3×6 mm³) that uses proprietary osmotic pressure technology. It lasts a minimum of six months, requires no calibration, and transmits glucose data directly to smart devices. The system comprises the sensor core, transmitter electronics, and a mobile medical application.
- Lifecare Veterinary (Sencell for veterinary use) Lifecare Veterinary adapts the Sencell glucose monitoring platform for use in diabetic dogs and cats, distributing sensor, transmitter, and mobile app through veterinary clinics. The Norwegian Veterinary market had no specific regulatory requirements for medical devices for animals, enabling faster commercial entry.
- RemovAid Implant Removal Device RemovAid is a CE-approved Class IIa medical device under MDR 2017/745 for removing single-rod subdermal contraceptive implants. The device is ISO 13485:2016 certified and is also intended for removal of the Sencell glucose sensor from humans and pets.
- Lifecare Laboratory Services Commercial laboratory services provided by Lifecare Laboratory GmbH (Mainz, Germany) for clinical research and tests for pharmaceutical and biotechnical industries during drug and medical device approval, plus general laboratory services for medical institutions. ISO 9001 and ISO 13485 certified.
Quantifiable outcome
- Six-month implant longevity demonstrated with no adverse tissue response in vivo
- +5 more outcomes
Companies that use LIFECARE AS
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles3 records
LIFECARE AS technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
LIFECARE AS partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- RemovAid AScoreLifecare acquired 81.1% stake in RemovAid AS for NOK 2 million through a private placement in April 2024. RemovAid has developed a CE-approved Class IIa medical device for removal of subdermal implants. Lifecare plans to adapt RemovAid's implant removal technology for use with its Sencell glucose monitoring sensors, enabling removal of the sensor from humans and pets. The acquisition also opens access to RemovAid's existing distribution network in Norway and planned expansion to Sub-Saharan Africa.
- University of BathcoreClose collaboration with the University of Bath, UK for further development of the chemical composition for use in Sencell. The chemical composition is a core part of the technology and forms the basis for accurate, reliable, and immediate measurement of glucose. Lifecare Chemistry Ltd is a spin-off from this research collaboration, with Professor Tony James (25 international patents) as the named inventor.
- Goethe University FrankfurtcoreCollaboration with Goethe University of Frankfurt (Germany) for further developments of nanoscale pressure sensor technology, including microelectronic interfaces and related technologies.
- Norwegian University of Life Sciences (NMBU)coreImportant collaboration with the Norwegian University of Life Sciences ensuring veterinary-specific R&D, including market-oriented studies that will strengthen both the veterinary and the human market preparations of the technology. The LFC-SEN-002 longevity study is conducted in cooperation with the Faculty of Veterinary Medicine, Department of Companion Animal Clinical Sciences.
- SanofiminorLifecare entered a Product Development Agreement with Sanofi in the 2015-2020 period. Sanofi provided milestone-based funding contributions in return for a right of first refusal to negotiate an exclusive license to the Sencell technology.
- LINK MedicalcoreLifecare engaged LINK Medical as advisor for regulatory re-submission to the Norwegian Medical Products Agency (NOMA) following feedback that the submitted documentation was insufficient to support authorization for first-in-human clinical investigation. LINK Medical provides regulatory expertise for the clinical trial application process.
Scale indicators9 records
Recent moves8 records
Expansion highlights6 records
LIFECARE AS competitors and assessment
Company assessmentBroad incumbents
- Medtronic Diabetes: Medtronic sells the Guardian CGM system and the MiniMed insulin pump. As a broad incumbent in diabetes management, Medtronic combines CGM with closed-loop insulin delivery—a system play that Lifecare would need to address via partnerships or platform extension.
- Dexcom: Dexcom is the leading standalone CGM manufacturer (G6, G7), dominating the U.S. and global CGM market with established payor coverage. As a broad incumbent in continuous glucose monitoring, Dexcom represents the primary external wearable-CGM competitor Lifecare will face at commercial launch.
- Abbott Diabetes Care: Abbott's FreeStyle Libre is the highest-volume CGM globally and Abbott's 2025 acquisition of Senseonics makes it the only company with both an external (Libre) and long-duration implantable (Eversense) CGM portfolio. Lifecare's Sencell will compete most directly with this combined offering.
- PHC Holdings (Ascensia Diabetes Care): Ascensia (PHC subsidiary) sells the Eversense implantable CGM in select markets following its partnership transition from Senseonics, and also markets the CONTOUR blood glucose monitoring line. As a broad incumbent with implantable CGM distribution rights, Ascensia is a relevant competitor to Lifecare's planned CE-marked launch.
Emerging players
- Biolinq: Biolinq is developing an intradermal biosensor patch for continuous metabolic monitoring including glucose. As an emerging player with a minimally invasive, miniaturized sensor approach, Biolinq is a partial competitor to Lifecare's grain-of-rice implantable concept.
- Nemaura Medical: Nemaura developed sugarBEAT, a non-invasive wearable CGM patch. As an emerging CGM player targeting continuous glucose monitoring with a differentiated delivery form factor, Nemaura competes for the same patient population that Lifecare's Sencell targets.
Regional players
- A. Menarini Diagnostics: Menarini distributes the GlucoMen Day CGM across Europe. As a regional incumbent with comparable European distribution and clinical relationships, Menarini represents Lifecare's most relevant European market entry competitor.
Others
- Insulet: Insulet's Omnipod 5 is a tubeless insulin patch pump integrated with CGM. As an adjacent diabetes-management player focused on delivery rather than sensing, Insulet represents a potential partner or acquirer for Lifecare's sensor platform within closed-loop diabetes systems.
- EOFlow: EOFlow developed a tubeless patch insulin pump (EOPatch). As an adjacent wearable diabetes-device player, EOFlow represents the kind of small-cap competitor or partner ecosystem member that Lifecare could either partner with or compete against for diabetes patient share.
Direct peers
- Senseonics Holdings: Senseonics developed the Eversense 6-month implantable CGM, the closest direct competitor to Lifecare's Sencell in form factor and longevity. Senseonics was acquired by Abbott in 2025, validating the implantable CGM opportunity while also creating a major incumbent threat to Lifecare.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
LIFECARE AS social profiles
Digital presenceLIFECARE AS compliance and trust
Trust signalCompliance3 records
LIFECARE AS financial estimates
Financial estimateRevenue estimate
Valuation estimate
LIFECARE AS leadership team
Management profileNumber of profiles
Profiles10 records
LIFECARE AS subsidiaries and ownership
Company hierarchySubsidiaries6 records
LIFECARE AS funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
LIFECARE AS M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about LIFECARE AS
What does LIFECARE AS do?
Lifecare AS develops miniaturized implantable nanobiosensors for continuous glucose monitoring, with Sencell as its core product: a wireless implantable CGM sensor approximately the size of a grain of rice (2×3×6 mm³) that uses proprietary osmotic pressure technology, requires no calibration, and lasts a minimum of six months. The portfolio also includes RemovAid (CE-approved Class IIa device for subdermal implant removal), Lifecare Veterinary (Sencell-based glucose monitoring for diabetic dogs and cats), and laboratory services for clinical research. Products are sold through healthcare and veterinary clinics, with commercialization targeted after CE marking.
Is LIFECARE AS a public or private company?
LIFECARE AS is a public company. It is classified as public and is currently operating.
When was LIFECARE AS founded?
LIFECARE AS was founded in 1998. It employs 11 to 50 people.
Where is LIFECARE AS based?
LIFECARE AS is headquartered in Bergen, Norway, in the Europe region.
How does LIFECARE AS make money?
Four revenue lines are on record. Implantable CGM Sensor Sales (Human) is the primary driver. The others are veterinary Glucose Monitoring System Sales, removAid Device Sales and laboratory Services.
Who are LIFECARE AS's main competitors?
Broad incumbents on record are Medtronic Diabetes, Dexcom, Abbott Diabetes Care and PHC Holdings (Ascensia Diabetes Care). Emerging players are Biolinq and Nemaura Medical. A. Menarini Diagnostics is listed as a regional player. Others are Insulet and EOFlow. Senseonics Holdings is listed as a direct peer.
Does LIFECARE AS have an API?
No public API is recorded for LIFECARE AS.
What industry is LIFECARE AS in?
LIFECARE AS's product category is Continuous Glucose Monitoring Devices. Its primary akta.pro industry code is HLAHAHAA, Continuous Glucose Monitoring (CGM) Systems, with a secondary code of HLAGAGAF, Analytical Development & QC Testing (Release/Stability/Potency). Its NAICS code is 334510 and its SIC code is 3845.